Vir Biotechnology Inc.
03/04/2026 | Press release | Distributed by Public on 03/04/2026 15:02
Management Change/Compensation (Form 8-K)
| Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On March 4, 2026, the Board of Directors of Vir Biotechnology, Inc. (Vir Bio) appointed Marianne De Backer, M.Sc., Ph.D., MBA, Vir Bio's Chief Executive Officer and principal executive officer, to the additional position of President.
Biographical information regarding Dr. De Backer that is responsive to Items 401(b) and (e) of Regulation S-Kis incorporated by reference herein from Vir Bio's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 17, 2025.
There are no arrangements or understandings between Dr. De Backer and any other person pursuant to which she was named as President of Vir Bio, and there is no family relationship between Dr. De Backer and any of Vir Bio's directors or executive officers. Dr. De Backer has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Vir Biotechnology Inc. published this content on March 04, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 04, 2026 at 21:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]